CITIUS ONCOLOGY INC

Historical 13F Holders

Symbol: CTOR
CUSIP: 17331Y109
All holders as of: Q2 2026
Type: Equity
Class: COM

Reported Value, Excluding Options

Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 17331Y109 since 12/18/2024, newest first.

Filer	% of Class	Shares	Form	Filed
Armistice Capital, LLC 13G/A Amendment 4	10.0%	9,353,553	13G/A Amendment 4	8/14/2026 Event 6/30/2026
Armistice Capital, LLC	10.0%	9,353,553
Steven Boyd	10.0%	9,353,553
Citius Pharmaceuticals, Inc. 13D/A Amendment 4	71.0%	66,049,615	13D/A Amendment 4	6/4/2026 Event 5/15/2026
Armistice Capital, LLC 13G/A Amendment 3	10.0%	9,299,917	13G/A Amendment 3	5/15/2026 Event 3/31/2026
Armistice Capital, LLC	10.0%	9,299,917
Steven Boyd	10.0%	9,299,917
Armistice Capital, LLC 13G/A Amendment 2	10.0%	8,078,404	13G/A Amendment 2	2/17/2026 Event 12/31/2025
Armistice Capital, LLC	10.0%	8,078,404
Steven Boyd	10.0%	8,078,404
Citius Pharmaceuticals, Inc. 13D/A Amendment 3	77.9%	66,049,615	13D/A Amendment 3	12/17/2025 Event 12/10/2025
Armistice Capital, LLC 13G	9.8%	7,675,911	13G	11/14/2025 Event 9/30/2025
Armistice Capital, LLC	9.8%	7,675,911
Steven Boyd	9.8%	7,675,911
Citius Pharmaceuticals, Inc. 13D/A Amendment 2	79.1%	66,049,615	13D/A Amendment 2	9/12/2025 Event 9/10/2025
Citius Pharmaceuticals, Inc. 13D/A Amendment 1	84.3%	66,049,615	13D/A Amendment 1	7/25/2025 Event 7/17/2025

13F Holders by Quarter

Period	Filings	Shares, Excl. Options	Value, Excl. Options	Options Value
2026 Q2	19	14.1 M	$9.20 M	$0
2026 Q1	14	14.2 M	$8.83 M	$0
2025 Q4	18	6.86 M	$6.86 M	$0
2025 Q3	16	8.36 M	$17.0 M	$0
2025 Q2	8	227 k	$990 k	$0
2025 Q1	7	105 k	$97.7 k	$0
2024 Q4	12	201 k	$230 k	$0
2024 Q3	8	41.2 k	$57.0 k	$0